- The FDA has granted Fast Track designation to NuCana plc's NCNA Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer.
- The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: NCNA stock is up 24.50% at $2.95 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
